Skip to main content

NASDAQ:HOLX - Hologic Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $86.53
  • Forecasted Upside: 38.14 %
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
$62.64
▼ -1.1 (-1.73%)
1 month | 3 months | 12 months
Get New Hologic Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HOLX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HOLX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$86.53
▲ +38.14% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Hologic in the last 3 months. The average price target is $86.53, with a high forecast of $110.00 and a low forecast of $64.00. The average price target represents a 38.14% upside from the last price of $62.64.

Buy

The current consensus among 14 polled investment analysts is to buy stock in Hologic. This rating has held steady since September 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
11/24/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
2/22/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
5/22/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
8/20/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
11/18/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
2/16/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/17/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/6/2021Morgan StanleyLower Price TargetEqual Weight$84.00 ➝ $77.00Low
i
5/5/2021SVB LeerinkLower Price TargetOutperform$94.00 ➝ $85.00Low
i
5/5/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellLower Price TargetBuy$90.00 ➝ $80.00Low
i
4/30/2021Morgan StanleyLower Price TargetEqual Weight$84.00 ➝ $77.00Medium
i
4/29/2021CitigroupLower Price Target$90.00 ➝ $80.00Low
i
4/29/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellLower Price TargetBuy$90.00 ➝ $80.00High
i
4/29/2021SVB LeerinkLower Price TargetOutperform$94.00 ➝ $85.00High
i
4/5/2021Jefferies Financial GroupBoost Price TargetBuy$106.00 ➝ $110.00Low
i
3/1/2021Robert W. BairdBoost Price TargetBuy$84.00 ➝ $91.00Low
i
2/22/2021Robert W. BairdReiterated RatingBuy$84.00 ➝ $91.00Low
i
2/22/2021BTIG ResearchBoost Price TargetBuy$84.00 ➝ $91.00Medium
i
1/28/2021Wells Fargo & CompanyBoost Price TargetOverweight$90.00 ➝ $95.00Medium
i
1/6/2021Raymond JamesReiterated RatingBuyN/A
i
12/15/2020Morgan StanleyBoost Price TargetEqual Weight$80.00 ➝ $84.00Low
i
12/8/2020ArgusBoost Price Target$85.00 ➝ $100.00Low
i
11/20/2020Needham & Company LLCDowngradeBuy ➝ HoldLow
i
Rating by Michael Matson at Needham & Company LLC
11/9/2020Morgan StanleyBoost Price TargetEqual Weight$68.00 ➝ $80.00High
i
11/5/2020Jefferies Financial GroupBoost Price Target$80.00 ➝ $98.00Low
i
11/5/2020Smith Barney CitigroupBoost Price Target$90.00 ➝ $85.00Low
i
11/5/2020UBS GroupBoost Price TargetNeutral$77.00 ➝ $81.00Low
i
11/5/2020JPMorgan Chase & Co.Boost Price TargetOverweight$75.00 ➝ $85.00High
i
11/5/2020Wells Fargo & CompanyBoost Price TargetOverweight$80.00 ➝ $90.00High
i
11/5/2020Raymond JamesBoost Price TargetOutperform$75.00 ➝ $86.00Medium
i
11/5/2020SVB LeerinkBoost Price TargetOutperform$80.00 ➝ $94.00Low
i
11/5/2020Needham & Company LLCBoost Price TargetBuy$78.00 ➝ $88.00Medium
i
Rating by Michael Matson at Needham & Company LLC
8/26/2020Needham & Company LLCReiterated RatingBuy$78.00Low
i
Rating by Michael Matson at Needham & Company LLC
7/31/2020Morgan StanleyBoost Price TargetEqual Weight$55.00 ➝ $68.00Low
i
7/30/2020Wells Fargo & CompanyBoost Price TargetOverweight$63.00 ➝ $80.00High
i
7/30/2020Raymond JamesBoost Price TargetOutperform$68.00 ➝ $78.00High
i
7/30/2020CitigroupBoost Price TargetPositive ➝ Buy$63.00 ➝ $85.00Low
i
7/30/2020SVB LeerinkBoost Price TargetOutperform$66.00 ➝ $80.00Low
i
Rating by R. Newitter at SVB Leerink LLC
7/30/2020Needham & Company LLCBoost Price TargetBuy$64.00 ➝ $78.00Low
i
Rating by Michael Matson at Needham & Company LLC
7/29/2020BTIG ResearchReiterated RatingBuy$63.00 ➝ $84.00Low
i
Rating by Ryan Zimmerman at BTIG Research
7/27/2020William BlairReiterated RatingOutperformLow
i
Rating by B. Weinstein at William Blair
7/23/2020Raymond JamesBoost Price TargetOutperform$62.00 ➝ $68.00Low
i
7/15/2020SVB LeerinkBoost Price TargetOutperform$62.00 ➝ $66.00Low
i
Rating by R. Newitter at SVB Leerink LLC
7/1/2020Needham & Company LLCInitiated CoverageBuy$60.00 ➝ $64.00High
i
Rating by Michael Matson at Needham & Company LLC
6/30/2020CowenUpgradeMarket Perform ➝ Outperform$64.00High
i
6/26/2020BTIG ResearchReiterated RatingBuy$60.00Low
i
Rating by Ryan Zimmerman at BTIG Research
6/16/2020BTIG ResearchBoost Price TargetBuy$54.00 ➝ $60.00Low
i
6/10/2020Needham & Company LLCReiterated RatingBuyLow
i
Rating by Michael Matson at Needham & Company LLC
6/9/2020Morgan StanleyBoost Price TargetEqual Weight$53.00 ➝ $55.00Low
i
6/3/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$62.00Medium
i
6/2/2020Needham & Company LLCInitiated CoverageBuy$60.00High
i
Rating by Michael Matson at Needham & Company LLC
4/30/2020JPMorgan Chase & Co.Boost Price TargetOverweight$45.00 ➝ $55.00High
i
4/30/2020Morgan StanleyBoost Price TargetEqual Weight$40.00 ➝ $53.00High
i
4/30/2020Wells Fargo & CompanyBoost Price TargetOverweight$48.00 ➝ $60.00High
i
4/30/2020BTIG ResearchBoost Price TargetBuy$46.00 ➝ $54.00High
i
4/30/2020SVB LeerinkUpgradeMarket Perform ➝ Outperform$41.00 ➝ $62.00High
i
Rating by Richard Newitter at SVB Leerink LLC
4/30/2020Needham & Company LLCBoost Price TargetBuy$52.00 ➝ $60.00High
i
Rating by Michael Matson at Needham & Company LLC
4/28/2020UBS GroupLower Price TargetNeutral$58.00 ➝ $52.00Low
i
4/19/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ OverweightMedium
i
4/8/2020SVB LeerinkLower Price TargetMarket Perform$57.00 ➝ $41.00High
i
Rating by Richard Newitter at SVB Leerink LLC
4/8/2020Stifel NicolausLower Price TargetHold$52.00 ➝ $45.00High
i
4/8/2020William BlairReiterated RatingOutperformHigh
i
Rating by Brian Weinstein at William Blair
4/7/2020BTIG ResearchReiterated RatingPositive ➝ Buy$54.00 ➝ $46.00Low
i
4/7/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$48.00High
i
4/2/2020Needham & Company LLCUpgradeBuy$62.00 ➝ $52.00High
i
3/27/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$53.00 ➝ $40.00Low
i
3/26/2020BarclaysLower Price TargetEqual Weight$51.00 ➝ $43.00High
i
3/17/2020JPMorgan Chase & Co.Lower Price TargetOverweight$60.00 ➝ $50.00High
i
1/30/2020Piper SandlerBoost Price Target$58.00 ➝ $61.00Low
i
1/30/2020BTIG ResearchReiterated RatingBuy$54.00Medium
i
1/13/2020BarclaysBoost Price TargetEqual Weight$50.00 ➝ $51.00Low
i
1/13/2020Needham & Company LLCBoost Price TargetBuy$57.00 ➝ $62.00Low
i
1/7/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$57.00Low
i
1/6/2020CitigroupInitiated CoverageBuy$60.00Low
i
1/2/2020Morgan StanleyDowngradeEqual Weight ➝ UnderweightLow
i
12/17/2019Morgan StanleyBoost Price TargetUnderweight$45.00 ➝ $50.00Low
i
12/13/2019Stifel NicolausBoost Price TargetHold$48.00 ➝ $52.00Low
i
11/21/2019William BlairReiterated RatingBuyLow
i
Rating by Brian Weinstein at William Blair
11/20/2019SVB LeerinkReiterated RatingHold$50.00Medium
i
Rating by Richard Newitter at SVB Leerink LLC
9/26/2019Bank of AmericaUpgradeNeutral ➝ Buy$54.00 ➝ $59.00High
i
8/14/2019ArgusBoost Price TargetBuy$62.00High
i
8/5/2019Stifel NicolausBoost Price TargetHold$43.00 ➝ $48.00Medium
i
8/1/2019Piper Jaffray CompaniesBoost Price TargetOverweight$49.00 ➝ $59.00Low
i
8/1/2019Canaccord GenuityReiterated RatingHold$52.00Low
i
8/1/2019BTIG ResearchReiterated RatingBuy$52.00High
i
8/1/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$52.00 ➝ $57.00High
i
7/10/2019Needham & Company LLCReiterated RatingBuy$52.00Low
i
5/2/2019BTIG ResearchReiterated RatingBuy$52.00Low
i
5/2/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$50.00 ➝ $52.00Medium
i
4/2/2019Needham & Company LLCReiterated RatingBuy$50.00Low
i
1/31/2019BTIG ResearchReiterated RatingBuy$50.00High
i
1/31/2019Piper Jaffray CompaniesBoost Price TargetIn-Line ➝ Overweight$49.00High
i
1/31/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$48.00 ➝ $50.00High
i
1/14/2019Needham & Company LLCReiterated RatingBuy$48.00Low
i
1/7/2019Canaccord GenuityReiterated RatingHold$41.00High
i
1/4/2019CowenDowngradeOutperform ➝ Market Perform$38.28Medium
i
1/2/2019Morgan StanleyDowngradeEqual Weight ➝ Underweight$44.00 ➝ $39.00High
i
11/30/2018Royal Bank of CanadaBoost Price TargetSector Perform ➝ Sector Perform$40.00 ➝ $46.00Low
i
11/8/2018Canaccord GenuityReiterated RatingHold$43.00Low
i
11/8/2018Piper Jaffray CompaniesLower Price TargetOverweight$45.00N/A
i
10/11/2018Morgan StanleyLower Price TargetEqual Weight$47.00 ➝ $44.00Medium
i
10/9/2018UBS GroupInitiated CoverageNeutral ➝ Neutral$44.00Medium
i
9/27/2018Canaccord GenuityBoost Price TargetHold ➝ Hold$40.00 ➝ $41.00Low
i
9/27/2018Needham & Company LLCReiterated RatingBuy$48.00N/A
i
9/13/2018Canaccord GenuityLower Price TargetHold$41.00 ➝ $40.00Low
i
9/13/2018Bank of AmericaDowngradeBuy ➝ Neutral$47.00 ➝ $42.00High
i
9/5/2018BarclaysDowngradeOverweight ➝ Equal Weight$50.00 ➝ $43.00High
i
8/20/2018Deutsche Bank AktiengesellschaftLower Price TargetHold ➝ Hold$45.00 ➝ $43.00Low
i
Rating by Dan Leonard at Deutsche Bank Aktiengesellschaft
8/14/2018Canaccord GenuityLower Price TargetHold ➝ Hold$42.00 ➝ $41.00Medium
i
8/13/2018Needham & Company LLCReiterated RatingBuy$48.00High
i
8/2/2018BTIG ResearchReiterated RatingBuy$47.00Medium
i
8/1/2018CowenReiterated RatingBuy$45.00Medium
i
8/1/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$44.00 ➝ $47.00Medium
i
8/1/2018Jefferies Financial GroupReiterated RatingBuy$50.00Medium
i
8/1/2018Deutsche Bank AktiengesellschaftBoost Price TargetHold ➝ Hold$42.00 ➝ $45.00High
i
Rating by Dan Leonard at Deutsche Bank Aktiengesellschaft
8/1/2018Needham & Company LLCBoost Price TargetBuy$43.00 ➝ $48.00High
i
5/6/2018BTIG ResearchReiterated RatingBuy$44.00Medium
i
5/3/2018BarclaysLower Price TargetOverweight ➝ Overweight$54.00 ➝ $50.00High
i
5/3/2018Deutsche Bank AktiengesellschaftLower Price TargetHold ➝ Hold$44.00 ➝ $42.00High
i
Rating by Dan Leonard at Deutsche Bank Aktiengesellschaft
5/3/2018Stifel NicolausLower Price TargetHold ➝ Hold$42.00 ➝ $40.00High
i
5/3/2018SVB LeerinkDowngradeOutperform ➝ Market Perform$48.00 ➝ $41.00High
i
Rating by R. Newitter at SVB Leerink LLC
5/3/2018Canaccord GenuityDowngradeBuy ➝ Hold$48.00 ➝ $39.00High
i
5/1/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$50.00 ➝ $43.00Low
i
4/17/2018The Goldman Sachs GroupSet Price TargetBuy$43.00Low
i
Rating by Isaac Ro at The Goldman Sachs Group, Inc.
3/26/2018The Goldman Sachs GroupDowngradeConviction-Buy ➝ Buy$43.00Low
i
2/9/2018Canaccord GenuityReiterated RatingBuy$48.00Low
i
2/9/2018Royal Bank of CanadaReiterated RatingHold$44.00High
i
2/9/2018Needham & Company LLCReiterated RatingBuy$50.00High
i
2/9/2018Stifel NicolausDowngradeBuy ➝ Hold$45.00 ➝ $42.00High
i
2/1/2018Needham & Company LLCReiterated RatingBuy$50.00Low
i
1/19/2018Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$49.00Medium
i
1/9/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$48.00 ➝ $50.00Low
i
1/4/2018Bank of AmericaUpgradeNeutral ➝ Buy$50.00Low
i
Rating by Derik De Bruin at Bank of America Co.
1/3/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$50.00Medium
i
12/20/2017CowenUpgradeBuy$52.00Low
i
12/11/2017CowenUpgradeMarket Perform ➝ Outperform$51.00High
i
12/8/2017The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy$45.00 ➝ $50.00Low
i
Rating by Isaac Ro at The Goldman Sachs Group, Inc.
12/5/2017Needham & Company LLCReiterated RatingBuy ➝ Buy$46.00 ➝ $48.00Low
i
11/9/2017Piper Jaffray CompaniesReiterated RatingBuy$48.00N/A
i
11/3/2017Needham & Company LLCReiterated RatingBuy$50.00N/A
i
10/10/2017Jefferies Financial GroupReiterated RatingBuy$49.00 ➝ $44.00N/A
i
Rating by Steven Desanctis at Jefferies Financial Group Inc.
10/9/2017Stifel NicolausReiterated RatingBuy ➝ Buy$48.00 ➝ $45.00N/A
i
10/2/2017Needham & Company LLCReiterated RatingBuy$50.00Medium
i
9/22/2017Royal Bank of CanadaReiterated RatingHold$42.00Low
i
8/9/2017BarclaysReiterated RatingEqual Weight$53.00 ➝ $51.00Low
i
Rating by Jack Meehan at Barclays PLC
8/9/2017Royal Bank of CanadaReiterated RatingSector Perform$50.00 ➝ $45.00Low
i
8/3/2017BarclaysLower Price TargetOverweight$53.00 ➝ $51.00Medium
i
Rating by Jack Meehan at Barclays PLC
8/3/2017Deutsche Bank AktiengesellschaftLower Price TargetBuy$51.00 ➝ $49.00Medium
i
8/3/2017The Goldman Sachs GroupDowngradeConviction-Buy ➝ Buy$48.00 ➝ $47.00High
i
8/3/2017Royal Bank of CanadaLower Price TargetSector Perform ➝ Sector Perform$50.00 ➝ $45.00High
i
8/1/2017Needham & Company LLCReiterated RatingBuyMedium
i
7/21/2017Bank of AmericaReiterated RatingNeutral$44.00 ➝ $48.00Low
i
7/17/2017BarclaysReiterated RatingOverweight$50.00 ➝ $53.00Low
i
Rating by Jack Meehan at Barclays PLC
7/14/2017Piper Jaffray CompaniesReiterated RatingBuy$51.00Medium
i
7/14/2017Stifel NicolausReiterated RatingBuyMedium
i
6/28/2017Jefferies Financial GroupReiterated RatingBuy$49.00Low
i
Rating by Steven Desanctis at Jefferies Financial Group Inc.
5/28/2017Jefferies Financial GroupSet Price TargetBuy$49.00Low
i
Rating by Steven Desanctis at Jefferies Financial Group Inc.
5/14/2017BTIG ResearchReiterated RatingBuy$47.00Low
i
5/11/2017Stifel NicolausBoost Price TargetBuy ➝ Buy$45.00 ➝ $48.00High
i
5/9/2017Canaccord GenuityReiterated RatingBuy$53.00Low
i
Rating by Mark Massaro at Canaccord Genuity
4/5/2017BarclaysSet Price TargetBuy$50.00Low
i
Rating by Jack Meehan at Barclays PLC
4/4/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$46.00 ➝ $50.00Medium
i
3/30/2017SVB LeerinkReiterated RatingOutperform$52.00Low
i
Rating by R. Newitter at SVB Leerink LLC
3/14/2017Piper Jaffray CompaniesReiterated RatingOverweight$51.00Low
i
3/13/2017Jefferies Financial GroupReiterated RatingBuy$46.00 ➝ $49.00Low
i
2/15/2017Needham & Company LLCUpgradeHold ➝ Buy$46.00N/A
i
2/15/2017Bank of AmericaDowngradeBuy ➝ NeutralN/A
i
2/5/2017BTIG ResearchReiterated RatingBuy$47.00N/A
i
1/23/2017Canaccord GenuitySet Price TargetBuy$48.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
1/18/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$48.00N/A
i
1/8/2017Jefferies Financial GroupReiterated RatingBuy$46.00N/A
i
1/4/2017Evercore ISIDowngradeBuy ➝ Hold$42.00N/A
i
1/4/2017Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$44.00 ➝ $48.00N/A
i
Rating by william quirk at Piper Jaffray Companies
12/16/2016Needham & Company LLCReiterated RatingHoldN/A
i
12/15/2016Canaccord GenuitySet Price TargetBuy$48.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
11/19/2016BarclaysSet Price TargetBuy$45.00N/A
i
Rating by Jack Meehan at Barclays PLC
11/3/2016Needham & Company LLCReiterated RatingHoldN/A
i
11/3/2016BTIG ResearchBoost Price TargetBuy$44.00 ➝ $47.00N/A
i
11/3/2016BarclaysReiterated RatingBuy$45.00N/A
i
Rating by jack meehan at Barclays PLC
11/3/2016SVB LeerinkReiterated RatingTop Pick$46.00 ➝ $43.00N/A
i
10/15/2016Evercore ISIReiterated RatingBuy$43.00N/A
i
10/3/2016SVB LeerinkReiterated RatingOutperform$46.00N/A
i
Rating by Richard Newitter at SVB Leerink LLC
9/23/2016BarclaysUpgradeEqual Weight ➝ Overweight$42.00 ➝ $44.00N/A
i
Rating by Jack Meehan at Barclays PLC
8/28/2016Piper Jaffray CompaniesSet Price TargetHold$44.00N/A
i
Rating by william quirk at Piper Jaffray Companies
8/1/2016Royal Bank of CanadaReiterated RatingSector Perform$37.00 ➝ $39.00N/A
i
8/1/2016Royal Bank of CanadaBoost Price TargetSector Perform$37.00 ➝ $39.00N/A
i
7/31/2016BarclaysReiterated RatingEqual Weight$42.00N/A
i
Rating by Jack Meehan at Barclays PLC
7/28/2016Canaccord GenuitySet Price TargetBuy$45.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
7/28/2016Needham & Company LLCReiterated RatingHoldN/A
i
Rating by Michael Matson at Needham & Company LLC
7/28/2016BTIG ResearchReiterated RatingBuy$44.00N/A
i
7/28/2016SVB LeerinkReiterated RatingBuy$46.00N/A
i
Rating by Richard Newitter at SVB Leerink LLC
7/28/2016Morgan StanleyBoost Price TargetEqual Weight$38.00 ➝ $40.00N/A
i
Rating by David Lewis at Morgan Stanley
7/28/2016Jefferies Financial GroupBoost Price TargetBuy$42.00 ➝ $43.00N/A
i
Rating by Raj Denhoy at Jefferies Financial Group Inc.
7/28/2016Evercore ISIUpgradeHold ➝ Buy$38.00 ➝ $42.00N/A
i
7/25/2016Piper Jaffray CompaniesSet Price TargetHold$40.00N/A
i
Rating by William Quirk at Piper Jaffray Companies
7/17/2016UBS GroupReiterated RatingBuy$45.00N/A
i
Rating by Jon Groberg at UBS Group AG
7/10/2016BarclaysReiterated RatingHold$42.00N/A
i
6/22/2016Bank of AmericaReiterated RatingBuyN/A
i
Rating by Derik De Bruin at Bank of America Co.
6/21/2016Jefferies Financial GroupReiterated RatingBuy$42.00N/A
i
Rating by Raj Denhoy at Jefferies Financial Group Inc.
6/6/2016UBS GroupReiterated RatingBuy$45.00N/A
i
Rating by Jon Groberg at UBS Group AG
6/4/2016Morgan StanleyReiterated RatingHoldN/A
i
Rating by David Lewis at Morgan Stanley
(Data available from 5/18/2016 forward)
Hologic logo
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. It has a collaboration with RadNet, Inc. to advance the use of artificial intelligence in breast health. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.
Read More

Today's Range

Now: $62.64
$62.57
$64.16

50 Day Range

MA: $70.98
$62.80
$76.68

52 Week Range

Now: $62.64
$49.19
$85.00

Volume

2,211,025 shs

Average Volume

2,156,254 shs

Market Capitalization

$16.05 billion

P/E Ratio

14.91

Dividend Yield

N/A

Beta

1.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Hologic?

The following Wall Street research analysts have issued reports on Hologic in the last year: Argus, BTIG Research, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Raymond James, Robert W. Baird, Smith Barney Citigroup, SVB Leerink LLC, UBS Group AG, Wells Fargo & Company, William Blair, and Zacks Investment Research.
View the latest analyst ratings for HOLX.

What is the current price target for Hologic?

15 Wall Street analysts have set twelve-month price targets for Hologic in the last year. Their average twelve-month price target is $86.53, suggesting a possible upside of 38.1%. Jefferies Financial Group Inc. has the highest price target set, predicting HOLX will reach $110.00 in the next twelve months. Cowen Inc has the lowest price target set, forecasting a price of $64.00 for Hologic in the next year.
View the latest price targets for HOLX.

What is the current consensus analyst rating for Hologic?

Hologic currently has 3 hold ratings and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HOLX will outperform the market and that investors should add to their positions of Hologic.
View the latest ratings for HOLX.

What other companies compete with Hologic?

How do I contact Hologic's investor relations team?

Hologic's physical mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider's listed phone number is 508-263-2900 and its investor relations email address is [email protected] The official website for Hologic is www.hologic.com.